Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal

Drew Armstrong

Executive Editor

Amber Tong

French drugmaker Sanofi showcased its vaccine franchise, part of a promise made two years ago to overhaul what the company at the time acknowledged was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal

Drew Armstrong

Executive Editor

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

Executive Editor

Sign up to read this article for free.

Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal